Individualized Precise Radiotherapy With the Guidance of Radiosensitivity of Locally Advanced Cervical Cancer
NCT03163979 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300
Last updated 2017-05-23
Summary
Cisplatin-based chemoradiation (CCRT) has been considered as the standard care for patients with locally advanced cervical cancer (LACC). Nevertheless, increasingly more radio-resistant tumors still recur. IMRT including Rapid-Arc have obvious advantage in the dose distribution and organ protection, and positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) and Comet analysis have good sensitivity for detecting sites and radiosensitivity of disease. These may be helpful to individualized CCRT of LACC.
Three hundred LACC patients are enrolled in the study, who were with FIGO stages IB2-IVA and had no para-aortic lymphadenopathy (\>10 mm) assessed by PET-CT or MRI. All the patients received definitive radiotherapy consisting of external beam whole pelvic RT and HDR-ICBT. The cumulative linear quadratic equivalent dose (EQD2) was 70-75Gy prescribed at point A. Cisplatin 30 mg/m2 weekly was administered concurrently for 5 courses. 2-4 cycles TP (Taxol 135 mg/m2, D1 and DDP 25 mg/m2, D1-3) regimen sequential chemotherapy were performed if complete response (CR) not achieved according to magnetic resonance imaging (MRI) or PET-CT after CCRT. Hypothesis of the study is that CCRT and sequential chemotherapy is safe. Based on FDG-PET/CT and Comet assay, higher doses can be safely delivered individually to accurate tumor volume, while the doses to bladder and rectum are relative low. Comet and FDG-PET/CT-guided IMRT including RapidArc may improve survival in terms of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) and less treatment-related toxicity. The data will be observed and analyzed.
Conditions
Interventions
- BIOLOGICAL
-
18F-FDG PET/CT and Comet assay guide RapidArc
1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
- BIOLOGICAL
-
18F-FDG PET/CT and Comet assay guide IMRT
Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
- BIOLOGICAL
-
RapidArc
RapidArc: A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used.
- BIOLOGICAL
-
7f-IMRT
seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
Sponsors & Collaborators
-
Nanjing Medical University
lead OTHER
Principal Investigators
-
Zhi-liang Ding · Health and Family Planning Commission of Jiangsu Province, China
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-07-01
- Primary Completion
- 2019-04-30
- Completion
- 2019-07-31
Countries
- China
Study Locations
More Related Trials
-
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
NCT06128460 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma
NCT01554410 ·Status: COMPLETED ·Phase: PHASE1
-
NAC Followed by RH for the Treatment of LACC
NCT03963882 ·Status: UNKNOWN ·Phase: PHASE2
-
Image Based Brachytherapy in Locally Advanced Cervical Cancers - a Randomized Controlled Trial
NCT03005743 ·Status: COMPLETED ·Phase: NA
-
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer
NCT02595554 ·Status: UNKNOWN ·Phase: PHASE3
-
Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy
NCT02957266 ·Status: UNKNOWN ·Phase: PHASE3
-
Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer
NCT01938105 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients
NCT01000415 ·Status: UNKNOWN ·Phase: PHASE3
-
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
NCT05173272 ·Status: RECRUITING ·Phase: PHASE3
-
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
NCT05735145 ·Status: RECRUITING ·Phase: PHASE3
-
Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients
NCT05504642 ·Status: WITHDRAWN ·Phase: PHASE2
-
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
NCT07088731 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Adjuvant Chemotherapy for Locally Advanced Cervical Cancer
NCT02036164 ·Status: UNKNOWN ·Phase: PHASE3
-
Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma
NCT04678791 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Reducing Radiation Target Volume for Stage IIb Cervical Cancer
NCT07249957 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer
NCT02703961 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
NCT06237257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.
NCT01973101 ·Status: UNKNOWN ·Phase: PHASE2
-
Palliative Radiation for Advanced Cervical Cancer
NCT03997110 ·Status: RECRUITING ·Phase: NA
-
Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer
NCT03249519 ·Status: RECRUITING ·Phase: NA
-
Study on Early Stage Bulky Cervical Cancers
NCT01917695 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer
NCT05189028 ·Status: RECRUITING ·Phase: PHASE3
-
Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients
NCT01756170 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer
NCT01461772 ·Status: TERMINATED ·Phase: PHASE3